Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Opzelura (ruxolitinib) is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable; and for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
• This summary is based on the review of nine systematic review(s)/meta-analysis(es). ^[1-9]
• Alopecia Areata (AA): Brepocitinib 30mg was most effective in reducing the SALT score and had the highest probability of achieving a SALT₅₀ response. Deuruxolitinib 12mg showed the highest probability of achieving a SALT₇₅ response. No population differences were noted.
• Atopic Dermatitis (AD) - Systemic and Topical Treatments: Dupilumab and upadacitinib demonstrated superior outcomes in EASI 90, IGA 0/1, EASI 75, and Pruritus NRS4, with ruxolitinib effective for EASI 75 and Pruritus NRS4 in mild to moderate AD. No population differences were noted.
• Vitiligo: Ruxolitinib showed a good response in 57.8% of cases, with the highest good response rate of 70% in facial vitiligo. Concurrent UVB phototherapy improved the treatment efficacy.
• Alopecia Areata (AA): Ruxolitinib cream demonstrated a relatively acceptable short-term safety profile; deuruxolitinib had a greater likelihood of causing adverse events, while ritlecitinib 50mg exhibited fewer adverse effects.
• Atopic Dermatitis (AD) - Systemic and Topical Treatments: Ruxolitinib showed a good safety profile and minimal risk of mild-to-moderate adverse effects. Baricitinib combined with TCS had a higher incidence of serious adverse events. Dupilumab combined with TCS demonstrated greater efficacy and safety.
• Adults and pediatric populations were included in studies on AD treatments, with delgocitinib showing great efficacy in pediatric AD; for vitiligo, facial vitiligo had the highest good response rate with JAK inhibitors, and concurrent UVB phototherapy improved efficacy.